Compare · KALV vs LLY
KALV vs LLY
Side-by-side comparison of KalVista Pharmaceuticals Inc. (KALV) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KALV and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.00T, about 698.7x KALV ($1.43B).
- Over the past year, KALV is up 101.4% and LLY is up 44.2% - KALV leads by 57.2 points.
- LLY has been more active in the news (21 items in the past 4 weeks vs 17 for KALV).
- LLY has more recent analyst coverage (25 ratings vs 8 for KALV).
- Company
- KalVista Pharmaceuticals Inc.
- Eli Lilly and Company
- Price
- $26.95-0.02%
- $1082.46+1.70%
- Market cap
- $1.43B
- $1.00T
- 1M return
- +0.99%
- +11.80%
- 1Y return
- +101.38%
- +44.17%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 17
- 21
- Recent ratings
- 8
- 25
KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which has completed Phase II clinical trial for an oral on-demand therapy for acute HAE attacks; and KVD824, an oral product candidate for the treatment of HAE. The company is headquartered in Cambridge, Massachusetts.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest KALV
- Amendment: SEC Form SC 14D9/A filed by KalVista Pharmaceuticals Inc.
- CHIEF DEVELOPMENT OFFICER Yea Christopher exercised 33,800 shares at a strike of $7.07 and sold $905,225 worth of shares (33,800 units at $26.78) (SEC Form 4)
- KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
- Chief Commercial Officer Sweeny Nicole sold $39,872 worth of shares (1,489 units at $26.78) and converted options into 5,000 shares, increasing direct ownership by 6% to 59,291 units (SEC Form 4) to cover withholding tax
- CHIEF MEDICAL OFFICER Audhya Paul K. converted options into 5,000 shares and sold $59,955 worth of shares (2,239 units at $26.78), increasing direct ownership by 2% to 150,260 units (SEC Form 4) to satisfy tax liability
- CHIEF DEVELOPMENT OFFICER Yea Christopher converted options into 3,125 shares and sold $52,645 worth of shares (1,966 units at $26.78), increasing direct ownership by 0.51% to 229,918 units (SEC Form 4) (tax liability)
- CHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 23,250 shares and sold $292,646 worth of shares (10,926 units at $26.78), increasing direct ownership by 3% to 479,989 units (SEC Form 4) (tax withholding)
- Chief Commercial Officer Sweeny Nicole converted options into 6,250 shares and sold $49,846 worth of shares (1,861 units at $26.78), increasing direct ownership by 9% to 55,780 units (SEC Form 4) to satisfy tax liability
- CHIEF DEVELOPMENT OFFICER Yea Christopher sold $63,158 worth of shares (2,358 units at $26.78) and converted options into 3,750 shares, increasing direct ownership by 0.61% to 228,759 units (SEC Form 4) to satisfy withholding obligation
- CHIEF MEDICAL OFFICER Audhya Paul K. converted options into 6,250 shares and sold $71,916 worth of shares (2,685 units at $26.78), increasing direct ownership by 2% to 147,499 units (SEC Form 4) to cover withholding tax
Latest LLY
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
- Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
- Foundayo and Zepbound now covered for millions of Americans
- Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
- Lilly announces three acquisitions to build infectious disease portfolio
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
- SEC Form 8-K filed by Eli Lilly and Company
- Director Sulzberger Gabrielle was granted 5 shares, increasing direct ownership by 0.17% to 2,987 units (SEC Form 4)